
Opinion|Videos|December 23, 2024
Assessing Patient Eligibility for CAR-T Therapy
This segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.
Advertisement
Video content above is prompted by the following:
- What factors make Rosie a strong candidate for CAR-T therapy?
- How do considerations like her age, overall fitness, and specifics of her relapse shape your decision?
- Are there other treatment paths you would explore for this patient?
- Let’s examine the data backing the use of ide-cel in this context:
- Which major findings from the KarMMa and KarMMa-3 trials are most relevant to your decision-making?
- How do these outcomes compare with other second-line options available for multiple myeloma?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Achieving a “Functional Cure” With Multiple Myeloma Therapy
2
ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
5


















































